Faron Presents Results from Melanoma Cohort of MATINS Trial at 18[th] Congress of the European Association of Dermato-Oncology (EADO)
Faron Pharmaceuticals Ltd. (“Faron” or “Company”) Faron Presents Results from Melanoma Cohort of MATINS Trial at 18th Congress of the European Association of Dermato-Oncology (EADO) · Compelling 30% clinical benefit rate seen following treatment with bexmarilimab in heavily pre-treated, checkpoint inhibitor refractory patient population · Analysis estimates 100% overall survival at 12-months for patients who experienced clinical benefit following treatment with bexmarilimab · Biomarker analysis shows melanoma patients with low baseline levels of inflammatory